The introduction of an anti-CD25 antibody that blocks the α-component of the IL-2 receptor (IL-2R) [5] and inhibits T-cell activation proved critical in recognizing the role of natural killer (NK) cells in MS, as these cells expanded with this therapy [6]. This evidence concerns the gene IL2RA and myeloid sarcoma.